ABNOM
☆ Germaniyaning 2022 yilgi Stiftung Warentest natijalariga ko'ra, iste'molchilarning ModelDermdan qoniqish darajasi pullik teletibbiyot maslahatlariga qaraganda bir oz pastroq bo'lgan.
References
Ma'lumki, Q-switched Nd:YAG lazer Ota nevusini va shunga o'xshash sharoitlarni samarali davolashadi. Biz high-fluence 1064 nm Q-switched Nd:YAG lazer g'ayrioddiy joylarda mo'g'ulcha dog'lar ustida terining yorug'ligiga olib kelmasdan qanchalik yaxshi ishlashini ko'rish uchun tadqiqot o'tkazdik. Biz ushbu dog'lar bo'lgan 61 bemorni o'rganib chiqdik, jami 70 ta jarohatni tekshirdik. Zararlarning yarmi lazer bilan davolangan, boshqalari esa taqqoslash uchun davolanmagan. Melanin darajasini o'lchash uchun Mexameter® deb nomlangan tarozi va qurilma yordamida natijalarni baholadik. Bemorlar davolash guruhida o'rtacha 14 oy va kuzatuv guruhida 18 oy davomida kuzatilgan. Tadqiqot oxirida biz davolangan va davolanmagan guruhlar o'rtasida shkala ko'rsatkichlari va melanin darajasida sezilarli farqlarni topdik, lazer bilan ishlov berilgan guruh yaxshi natijalarni ko'rsatdi. High-fluence Q-switched Nd:YAG lazer terini oqartirmasdan, bu noodatiy mo'g'ul dog'larini davolashda samarali va xavfsiz ekanligini isbotladi.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Biz ABNOM uchun maxsus lazer bilan davolashdan foydalanish samaradorligi va xavfsizligini o'rganib chiqdik va uning qanchalik yaxshi ishlashiga qanday omillar ta'sir qilishi mumkinligini ko'rib chiqdik. Biz ABNOM bo'lgan va ikki va to'qqizta lazer bilan davolashni olgan 110 bemorni ko'rib chiqdik. Davolanish qanchalik uzoq davom etsa, yaxshi samara berishini aniqladik, lekin keksa bemorlarda unchalik yaxshi emas. Bundan tashqari, terisi engilroq (III turdagi) va kichikroq ta'sirlangan joylar (10 sm2 dan kam) bo'lgan bemorlarda ham yaxshi ishladi. ABNOM bilan birga melazma bo'lishi davolanishni samarasiz qildi. Ta'sir qilingan joylarning rangi yoki soni farq qilmadi. Bemorlarning taxminan 10 foizida davolanishdan keyin qora dog'lar paydo bo'ldi. Erta ko'p davolash yaxshi natijalar berdi. Qorong'i teri va qora dog'lari bo'lgan keksa bemorlarda davolanishdan keyin qora dog'lar paydo bo'lishi ehtimoli ko'proq. ABNOM va melazma bilan og'rigan bemorlar uchun melazmani yomonlashtirmaslik uchun past energiyali lazerdan foydalanish yaxshiroqdir.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Davolash
Oqartiruvchi vositalar kamdan-kam yordam beradi. Melazmadan farqli o'laroq, ABNOM lazer bilan davolash bilan yaxshilanishi mumkin va takrorlanmasdan olib tashlanishi mumkin. ABNOMni davolash uchun lazer bilan davolash 10 dan 20 martagacha amalga oshirilishi mumkin.
#QS1064 laser